<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38444417</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Antidepressants for prevention of severe COVID-19, Long COVID and outlook for other viral diseases.</ArticleTitle><Pagination><StartPage>1305184</StartPage><MedlinePgn>1305184</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1305184</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2024.1305184</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bonnet</LastName><ForeName>Udo</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Mental Health, Evangelisches Krankenhaus Castrop-Rauxel, Academic Teaching Hospital of the University of Duisburg/Essen, Castrop-Rauxel, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Faculty of Medicine, Landschaftsverband Rheinland-Hospital Essen, University of Duisburg-Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juckel</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Psychotherapy and Preventive Medicine, LWL University Hospital, Ruhr University Bochum, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuhn</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Hospital Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alexianer Hospital Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">PACS</Keyword><Keyword MajorTopicYN="N">Post COVID</Keyword><Keyword MajorTopicYN="N">antidepressants</Keyword><Keyword MajorTopicYN="N">prevention</Keyword><Keyword MajorTopicYN="N">resilience</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>6</Day><Hour>3</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38444417</ArticleId><ArticleId IdType="pmc">PMC10912328</ArticleId><ArticleId IdType="doi">10.3389/fmed.2024.1305184</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hoertel N, S&#xe1;nchez-Rico M, Cougoule C, Gulbins E, Kornhuber J, Carpinteiro A, et al. . Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms. Mol Psychiatry. (2021) 26:7098&#x2013;9. 10.1038/s41380-021-01254-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01254-3</ArticleId><ArticleId IdType="pmc">PMC8359627</ArticleId><ArticleId IdType="pubmed">34385600</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnet U, Juckel G. COVID-19 outcomes: does the use of psychotropic drugs make a difference? Accumulating evidence of a beneficial effect of antidepressants-a scoping review. J Clin Psychopharmacol. (2022) 42:284&#x2013;92. 10.1097/JCP.0000000000001543</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JCP.0000000000001543</ArticleId><ArticleId IdType="pmc">PMC9042214</ArticleId><ArticleId IdType="pubmed">35420565</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenze E. Fluvoxamine for Early Treatment of COVID-19: A Fully-Remote, Randomized Placebo Controlled Trial. (2021). Available online at: http://clinicaltrials.gov (accessed 25 October, 2023).</Citation></Reference><Reference><Citation>Fritz BA, Hoertel N, Lenze EJ, Jalali F, Reiersen AM. Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2. Transl Psychiatry. (2022) 12:341. 10.1038/s41398-022-02109-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-022-02109-3</ArticleId><ArticleId IdType="pmc">PMC9395392</ArticleId><ArticleId IdType="pubmed">35995770</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineda E, Singh J, Pineda MV, Umanzor JG, Baires F, Benitez LG, et al. . Impact of fluvoxamine on outpatient treatment of COVID-19 in Honduras in a prospective observational real-world study. Front Pharmacol. (2022) 13:1054644. 10.3389/fphar.2022.1054644</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.1054644</ArticleId><ArticleId IdType="pmc">PMC9748291</ArticleId><ArticleId IdType="pubmed">36532727</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Huling JD, Tignanelli CJ, Buse JB, Liebovitz DM, Nicklas JM, et al. . Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. N Engl J Med. (2022) 387:599&#x2013;610. 10.1056/NEJMoa2201662</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2201662</ArticleId><ArticleId IdType="pmc">PMC9945922</ArticleId><ArticleId IdType="pubmed">36070710</ArticleId></ArticleIdList></Reference><Reference><Citation>Boretti A. Effectiveness of fluvoxamine at preventing COVID-19 infection from turning severe. Eur Neuropsychopharmacol. (2023) 67:83&#x2013;5. 10.1016/j.euroneuro.2022.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2022.12.001</ArticleId><ArticleId IdType="pmc">PMC9744705</ArticleId><ArticleId IdType="pubmed">36640691</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo H, Kim H, Bae S, Park S, Chung H, Sung HS, et al. . Fluvoxamine treatment of patients with symptomatic COVID-19 in a community treatment center: a preliminary result of randomized controlled trial. Infect Chemother. (2022) 54:102&#x2013;13. 10.3947/ic.2021.0142</Citation><ArticleIdList><ArticleId IdType="doi">10.3947/ic.2021.0142</ArticleId><ArticleId IdType="pmc">PMC8987178</ArticleId><ArticleId IdType="pubmed">35384422</ArticleId></ArticleIdList></Reference><Reference><Citation>Siripongboonsitti T, Ungtrakul T, Tawinprai K, Nimmol T, Buttakosa M, Sornsamdang G, et al. . Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study). Int J Infect Dis. (2023) 134:211&#x2013;9. 10.1016/j.ijid.2023.06.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.06.018</ArticleId><ArticleId IdType="pubmed">37393041</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy MW, Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Felker GM, et al. . Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV)-6 study group and investigators. Effect of fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial. JAMA. (2023) 329:296&#x2013;305. 10.1001/jama.2022.24100</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.24100</ArticleId><ArticleId IdType="pmc">PMC9857647</ArticleId><ArticleId IdType="pubmed">36633838</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedighi F, Zarghami M, Alizadeh Arimi F, Moosazadeh M, Ala S, Ghasemian R, et al. . Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non-critical COVID-19 pneumonia: a double-blind randomized, placebo-controlled clinical trial. Neuropsychopharmacol Rep. (2023) 43:202&#x2013;12. 10.1002/npr2.12327</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/npr2.12327</ArticleId><ArticleId IdType="pmc">PMC10275279</ArticleId><ArticleId IdType="pubmed">36941089</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoertel N, Rezaei K, S&#xe1;nchez-Rico M, Delgado-&#xc1;lvarez A, Kornhuber J, Gulbins E, et al. . Medications modulating the acid sphingomyelinase/ceramide system and 28-day mortality among patients with SARS-CoV-2: an observational study. Pharmaceuticals (Basel). (2023) 16:1107. 10.3390/ph16081107</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph16081107</ArticleId><ArticleId IdType="pmc">PMC10458150</ArticleId><ArticleId IdType="pubmed">37631022</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO (World Health Organization) . Post COVID-19 condition (Long COVID). (2022). Available online at: https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition (accessed 25 October, 2023).</Citation></Reference><Reference><Citation>El Mansari M, Ghanbari R, Janssen S, Blier P. Sustained administration of bupropion alters the neuronal activity of serotonin, norepinephrine but not dopamine neurons in the rat brain. Neuropharmacology. (2008) 55:1191&#x2013;8. 10.1016/j.neuropharm.2008.07.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2008.07.028</ArticleId><ArticleId IdType="pubmed">18708076</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DA, Seki SM, Fern&#xe1;ndez-Casta&#xf1;eda A, Beiter RM, Eccles JD, Woodfolk JA, et al. . Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med. (2019) 11:eaau5266. 10.1126/scitranslmed.aau5266</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau5266</ArticleId><ArticleId IdType="pmc">PMC6936250</ArticleId><ArticleId IdType="pubmed">30728287</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornhuber J, Hoertel N, Gulbins E. The acid sphingomyelinase/ceramide system in COVID-19. Mol Psychiatry. (2022) 27:307&#x2013;14. 10.1038/s41380-021-01309-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01309-5</ArticleId><ArticleId IdType="pmc">PMC8488928</ArticleId><ArticleId IdType="pubmed">34608263</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsiakalos A, Ziakas PD, Polyzou E, Schinas G, Akinosoglou K. Early fluvoxamine reduces the risk for clinical deterioration in symptomatic outpatients with COVID-19: a real-world, retrospective, before-after analysis. Microorganisms. (2023) 11:2073. 10.3390/microorganisms11082073</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11082073</ArticleId><ArticleId IdType="pmc">PMC10459506</ArticleId><ArticleId IdType="pubmed">37630633</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. (2008) 336:924&#x2013;6. 10.1136/bmj.39489.470347.AD</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39489.470347.AD</ArticleId><ArticleId IdType="pmc">PMC2335261</ArticleId><ArticleId IdType="pubmed">18436948</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirenga BJ, Mugenyi L, S&#xe1;nchez-Rico M, Kyobe H, Muttamba W, Mugume R, et al. . Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study. Mol Psychiatry. (2023). 10.1038/s41380-023-02004-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-023-02004-3</ArticleId><ArticleId IdType="pmc">PMC9982784</ArticleId><ArticleId IdType="pubmed">36869228</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenton C, Lee A. Antidepressants with anti-inflammatory properties may be useful in long COVID depression. Drugs Ther Perspect. (2023) 39:65&#x2013;70. 10.1007/s40267-022-00975-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40267-022-00975-x</ArticleId><ArticleId IdType="pmc">PMC9742030</ArticleId><ArticleId IdType="pubmed">36532316</ArticleId></ArticleIdList></Reference><Reference><Citation>Farahani RH, Ajam A, Naeini AR. Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial. BMC Infect Dis. (2023) 23:197. 10.1186/s12879-023-08172-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08172-5</ArticleId><ArticleId IdType="pmc">PMC10064948</ArticleId><ArticleId IdType="pubmed">37003990</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeng SH, Hong H. Inflammation as the potential basis in depression. Int Neurourol J. (2019) 23:S63&#x2013;71. 10.5213/inj.1938226.113</Citation><ArticleIdList><ArticleId IdType="doi">10.5213/inj.1938226.113</ArticleId><ArticleId IdType="pmc">PMC6905209</ArticleId><ArticleId IdType="pubmed">31795605</ArticleId></ArticleIdList></Reference><Reference><Citation>Milaneschi Y, Kappelmann N, Ye Z, Lamers F, Moser S, Jones PB, et al. . Association of inflammation with depression and anxiety: evidence for symptom-specificity and potential causality from UK Biobank and NESDA cohorts. Mol Psychiatry. (2021) 26:7393&#x2013;402. 10.1038/s41380-021-01188-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01188-w</ArticleId><ArticleId IdType="pmc">PMC8873022</ArticleId><ArticleId IdType="pubmed">34135474</ArticleId></ArticleIdList></Reference><Reference><Citation>Karimi Z, Chenari M, Rezaie F, Karimi S, Parhizgari N, Mokhtari-Azad T. Proposed pathway linking respiratory infections with depression. Clin Psychopharmacol Neurosci. (2022) 20:199&#x2013;210. 10.9758/cpn.2022.20.2.199</Citation><ArticleIdList><ArticleId IdType="doi">10.9758/cpn.2022.20.2.199</ArticleId><ArticleId IdType="pmc">PMC9048006</ArticleId><ArticleId IdType="pubmed">35466092</ArticleId></ArticleIdList></Reference><Reference><Citation>Czarny P, Wigner P, Galecki P, Sliwinski T. The interplay between inflammation, oxidative stress, DNA damage, DNA repair andmitochondrial dysfunction in depression. Prog Neuropsychopharmacol Biol Psychiatry. (2018) 80:309&#x2013;21. 10.1016/j.pnpbp.2017.06.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2017.06.036</ArticleId><ArticleId IdType="pubmed">28669580</ArticleId></ArticleIdList></Reference><Reference><Citation>Krapi&#x107; M, Kavazovi&#x107; I, Wensveen FM. Immunological mechanisms of sickness behavior in viral infection. Viruses. (2021) 13:2245. 10.3390/v13112245</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13112245</ArticleId><ArticleId IdType="pmc">PMC8624889</ArticleId><ArticleId IdType="pubmed">34835051</ArticleId></ArticleIdList></Reference><Reference><Citation>Rein T. Is autophagy involved in the diverse effects of antidepressants? Cells. (2019) 8:44. 10.3390/cells8010044</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8010044</ArticleId><ArticleId IdType="pmc">PMC6356221</ArticleId><ArticleId IdType="pubmed">30642024</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong RL, Kahn UN, Grafe LA, Hitti FL, Fried NT, Corbett BF. Stress circuitry: mechanisms behind nervous and immune system communication that influence behavior. Front Psychiatry. (2023) 14:1240783. 10.3389/fpsyt.2023.1240783</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2023.1240783</ArticleId><ArticleId IdType="pmc">PMC10495591</ArticleId><ArticleId IdType="pubmed">37706039</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xe1;cz B, Spengler G. Repurposing antidepressants and phenothiazine antipsychotics as efflux pump inhibitors in cancer and infectious diseases. Antibiotics (Basel). (2023) 12:137. 10.3390/antibiotics12010137</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics12010137</ArticleId><ArticleId IdType="pmc">PMC9855052</ArticleId><ArticleId IdType="pubmed">36671340</ArticleId></ArticleIdList></Reference><Reference><Citation>Golden SR, Rosenstein DL, Belhorn T, Blatt J. Repurposing psychotropic agents for viral disorders: beyond Covid. Assay Drug Dev Technol. (2021) 19:373&#x2013;85. 10.1089/adt.2021.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/adt.2021.014</ArticleId><ArticleId IdType="pubmed">34375133</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbasi J, A. Genetic explanation for why some people had asymptomatic COVID-19. JAMA. (2023) 330:683&#x2013;4. 10.1001/jama.2023.14703</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.14703</ArticleId><ArticleId IdType="pubmed">37531124</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>